Search results
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
Zacks via Yahoo Singapore Finance· 1 year agoFor those looking to find strong Medical stocks, it is prudent to search for companies in the group...
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Singapore Finance· 3 months agoExelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses...
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
Zacks via Yahoo Singapore Finance· 10 months agoShares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it...
AstraZeneca boosts heart, kidney business with $1.8 billion CinCor deal
Reuters via Yahoo Singapore Finance· 2 years ago(Reuters) -AstraZeneca said on Monday it had struck a deal to buy U.S.-based drug developer CinCor...
Europe's STOXX 600 ends earnings-heavy day on strong note
Reuters via Yahoo News· 2 years ago(Reuters) -Europe's STOXX 600 index closed near a seven-week high on Thursday, boosted by a slew of...
Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress
Zacks via Yahoo Singapore Finance· 8 months agoExelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop...
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
Zacks via Yahoo News· 2 years agoInvestors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL)...
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
Zacks via Yahoo News· 2 years agoExelixis, Inc. EXEL reported earnings of 22 cents in the second quarter of 2022, beating the Zacks...
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
Zacks via Yahoo Singapore Finance· 11 months agoExelixis, Inc. EXEL and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of...
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Zacks via Yahoo News· 2 years agoEpizyme, Inc. EPZM incurred a loss of 21 cents per share in second-quarter 2022, narrower than the...